– UK, London – Arix Bioscience plc (LON: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announced the appointments of James Noble and Dr. Axel Wieandt to its Board as Non-Executive Directors, effective 1 April 2021.
, alongside his current role as Chairman of the Audit Committee, with immediate effect.
The company also announced that Mark Breuer, Non-Executive Director, will step down from the Board on 1 April 2021, after serving on the Board for two years.
“We are delighted to announce that James and Axel are joining the Arix Board. They bring a wealth of experience that will be crucial in shaping the future strategy and success of the Company” said Executive Chairman, Dr. Naseem Amin.
He added: “On behalf of the Board, I would like to thank Mark Breuer for the commitment and invaluable support he has shown to the Company over the last two years.”
About James Noble
James Noble has extensive experience in the biotech industry. He is currently the Lead Independent Director and Deputy Chairman of GW Pharmaceuticals. He also serves as Chairman of Orexo AB, listed on the Stockholm Stock Exchange, and as a Director at Adaptimmune Therapeutics plc, a NASDAQ-listed company involved in T cell therapeutics, where he previously served as CEO.
James Noble was previously CEO of Avidex Limited, a private biotech company, and, until March 2014, was CEO of Immunocore Limited. Mr. Noble qualified as a chartered accountant with PriceWaterhouse in 1983 and then spent seven years at investment bank Kleinwort Benson Limited, where he became a Director in 1990. He then joined British Biotech plc as CFO and secured the company’s IPO on NASDAQ and London in 1992.
From 1997 to 2001, he held numerous non-executive director positions, including at PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, and Advanced Medical Solutions plc. Mr. Noble graduated from the University of Oxford in 1980.
About Dr. Axel Wieandt
Dr. Axel Wieandt is a senior financial service professional with expertise in banking, fintech, and finance. Dr. Wieandt started his career at Morgan Stanley, and then moved to Deutsche Bank as Head of Corporate Development and subsequently was also appointed Global Head of Corporate Investments. He was appointed CEO of Hypo Real Estate and then at the request of the German Deposit Insurance Fund, subsequently appointed CEO of Valovis Bank AG, where he remained until April 2015. Dr. Wieandt currently advises the US and European private equity firms, venture capital funds, and real estate companies on their investment and value creation strategies as well as acting as a senior advisor to several fintech and pharma companies.
Dr. Wieandt is a visiting faculty member in Finance at Goethe University in Frankfurt and the Kellogg School Graduate School of Management and is an honorary professor at WHU.
Mr. Wieandt earned a diploma in Business Management and Doctorate from the WHU Otto-Beisheim School of Management and an MBA from the Kellogg Graduate School of Management.
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we can bring this exciting growth phase of our industry to a broader range of investors.
For more information: https://arixbioscience.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.